Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 16/20 | 0.59 |
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7971736 | 0.81 | QRFPR (0.61) | QRFPRNOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL7598807 | 0.80 | QRFPR (0.60) | QRFPRNOS3NOS1NOS2 | |
| SCHEMBL7599383 | 0.74 | QRFPR (0.37) | QRFPR | |
| SCHEMBL7600942 | 0.71 | QRFPR (0.62) | QRFPRNOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL7598598 | 0.70 | QRFPR (0.61) | QRFPRNOS3NOS1NOS2 | |
| SCHEMBL7598794 | 0.70 | NOS3 (0.50) | QRFPRNOS3NOS1NOS2 | |
| SCHEMBL7960394 | 0.70 | CHRM2 (0.45) | — | |
| SCHEMBL7597204 | 0.69 | NOS1 (0.49) | QRFPRNOS3NOS1NOS2 | |
| SCHEMBL7602429 | 0.69 | NOS3 (0.49) | QRFPRNOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL7599083 | 0.69 | NOS1 (0.51) | QRFPRNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | claimed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046171-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137750-A1 | Amidine derivatives which are inhibitors of nitric oxide synthase | NOS1, NOS2, NOS3 | QRFPR 1455/4885NOS3 3/4885NOS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.